Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Johnson & Johnson, Janssen And Changzhou Yabang-QH Pharmachem To Jointly Establish Anti-Worm Drug Base

This article was originally published in PharmAsia News

Executive Summary

Johnson & Johnson, Janssen Pharmaceutica NV and Changzhou Yabang-QH Pharmachem recently began construction of their co-designed raw pharmaceutical materials base in Changzhou High-tech District. Of the total investment of about RMB 57 million, the first phase will receive a RMB 35 million capital injection. The facility, which is compliant with European and U.S. GMP, will go into production within this year. At the same time, the center will apply for Europe COS and FDA authentication with Janssen's aid. When completed, the facility will be China's largest anti-worm drug production, research and export base. Most of the expanded products will go to global high-end markets such as the U.S., Europe and Australia. (Click her for more - Chinese Language)

You may also be interested in...

QUOTED. 6 April 2020. Bethany Hills.

Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.

Health And Wellness Trademark Review 31 March, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Faster, Better? Fujitsu, Polarisqb 'Quantum-Inspired' Tech Speeds Discovery

Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts